Crescendo Biologics lands $28M to finance dermatology drug R&D
LONDON – Crescendo Biologics Ltd. has raised £17.5 million (US$28 million) in a Series A funding that will enable it to take antibody technology into a new arena, as the basis of topical treatments for dermatological diseases.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter